Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Inks Deal with WARF to Develop hESCs for Research Applications

NEW YORK (GenomeWeb News) - Invitrogen said today that it has licensed intellectual property from the Wisconsin Alumni Research Foundation that will enable it to develop research tools using human embryonic stem cells.
Under the terms of the agreement, the licensing organization for the University of Wisconsin-Madison has granted Invitrogen the right to work with karyotypically normal hESCs to develop research and drug discovery tools.
Joydeep Goswami, vice president of stem cells and regenerative medicine at Invitrogen, said in a statement that the agreement will enable Invitrogen to develop research tools "such as more defined media and engineered stem cell lines."
WARF said that it has now completed 24 licensing agreements for stem cell technologies with 18 companies.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.